Table 2. Multivariate analysis of the BCT score and the clinicopathological parameters for DMFS in pN0-N1, HR+/HER2− breast cancer patients treated with hormone therapy alone.
| Discovery cohort |
Validation cohort |
|||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P value | Hazard ratio | 95% CI | P value | |
| BCT score | 4.86 | (1.87–12.68) | 0.001 | 1.59 | (1.12–2.25) | 0.009 |
| Age at surgery | 1.04 | (0.98–1.11) | 0.158 | 1.02 | (0.96–1.09) | 0.460 |
| Tumor size | 0.54 | (0.14–2.11) | 0.374 | 1.23 | (0.60–2.50) | 0.566 |
| No. of LN metastasis | 0.89 | (0.26–3.03) | 0.858 | 0.21 | (0.03–1.57) | 0.129 |
| Histologic grade | 1.06 | (0.30–3.76) | 0.931 | 0.86 | (0.28–2.68) | 0.800 |
| ER (IHC) | 1.04 | (0.52–2.06) | 0.918 | 1.15 | (0.74–1.78) | 0.545 |
| PR (IHC) | 1.04 | (0.77–1.38) | 0.816 | 0.94 | (0.78–1.13) | 0.511 |
Abbreviations: CI, confidence interval; ER, estrogen receptor; IHC, immunohistochemistry; LN, lymph node; No, number; PR, progesterone receptor. Hazard ratios with P values < 0.05 are marked in bold.